Drugs / STSA-1301
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06148389 | Nov 2023 → Apr 2024 | primary thrombocytopenia | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06929299 | May 2025 → Jun 2026 overdue | autoimmune thrombocytopenia | Jiangsu BioJeTay Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STSA-1301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06929299 ↗ |
| Route | Subcutaneous | “STSA-1301 subcutaneous injection” NCT06148389 ↗ |